Novo Nordisk As Stock Five Year Return
| NVO Stock | USD 133.26 1.40 1.04% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
Novo | Five Year Return |
Novo Nordisk AS Company Five Year Return Analysis
Novo Nordisk's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current Novo Nordisk Five Year Return | 2.05 % |
Most of Novo Nordisk's fundamental indicators, such as Five Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novo Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Novo Nordisk is extremely important. It helps to project a fair market value of Novo Stock properly, considering its historical fundamentals such as Five Year Return. Since Novo Nordisk's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novo Nordisk's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novo Nordisk's interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
Novo Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, Novo Nordisk AS has a Five Year Return of 2.05%. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The five year return for all United States stocks is notably lower than that of the firm.
Novo Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in five year return category among related companies.
Novo Nordisk Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novo Nordisk from analyzing Novo Nordisk's financial statements. These drivers represent accounts that assess Novo Nordisk's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novo Nordisk's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 727.7B | 916.6B | 986.1B | 2.1T | 3.1T | 3.3T | |
| Enterprise Value | 712.6B | 905.6B | 983.7B | 2.1T | 3.1T | 3.3T |
Novo Nordisk ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novo Nordisk's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novo Nordisk's managers, analysts, and investors.Environmental | Governance | Social |
Novo Fundamentals
| Return On Equity | 1.0 | ||||
| Return On Asset | 0.25 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 610.4 B | ||||
| Shares Outstanding | 4.45 B | ||||
| Shares Owned By Institutions | 9.60 % | ||||
| Number Of Shares Shorted | 3.64 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 41.26 X | ||||
| Price To Sales | 2.42 X | ||||
| Revenue | 232.26 B | ||||
| Gross Profit | 148.51 B | ||||
| EBITDA | 112.94 B | ||||
| Net Income | 83.68 B | ||||
| Cash And Equivalents | 37.47 B | ||||
| Cash Per Share | 16.57 X | ||||
| Total Debt | 27.01 B | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 0.92 X | ||||
| Book Value Per Share | 22.18 X | ||||
| Cash Flow From Operations | 108.91 B | ||||
| Short Ratio | 1.01 X | ||||
| Earnings Per Share | 2.87 X | ||||
| Price To Earnings To Growth | 2.36 X | ||||
| Target Price | 146.76 | ||||
| Number Of Employees | 66.02 K | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 592.14 B | ||||
| Total Asset | 314.49 B | ||||
| Retained Earnings | 104.84 B | ||||
| Working Capital | (30.01 B) | ||||
| Current Asset | 8.03 B | ||||
| Current Liabilities | 5.95 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 2.05 % | ||||
| Net Asset | 314.49 B |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novo Nordisk Investors Sentiment
The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.
Novo Nordisk Implied Volatility | 43.15 |
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novo Nordisk Piotroski F Score and Novo Nordisk Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.87 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.